

EXHIBIT A

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete If Known

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	CHEUNG, Nai
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-B-PCT-US

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date
Considered

EXAMINER: Include if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Indicate copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is subject to the provisions of 28 CFR 17.101, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Additional time on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-B-PCT-US

Sheet 2 of 3

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	PCT Written Opinion for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH et al., Int'l appl No. PCT/US02/01276, (Atty. Dkt. #639-A-PCT), Filed January 15, 2002, Dated November 25, 2002.	
	4	PCT Corrected Written Opinion of the International Searching Authority for SLOAN Kettering Institute et al., Int'l Application No. PCT/US04/23099 (Atty. Dkt. #639-C-PCT), Filed July 16, 2004, Dated August 10, 2005.	
	5	RESEARCH et al., Int'l Application No. PCT/US2004/23099 (Atty. Dkt. #639-C-PCT), Filed July 16, 2004, Dated August 10, 2005.	
	6	PCT International Preliminary Report on Patentability for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH et al., Int'l Appl No. PCT/US2004/023099 (Atty. Dkt. #639-C-PCT), Filed July 16, 2004, Dated January 26, 2006.	
	7	PCT International Search Report for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, Int'l Application No. PCT/US07/01427 (Atty. Dkt. #639-F-PCT), Filed January 18, 2007, Dated September 26, 2007.	
	8	PCT Written Opinion of the International Searching Authority for SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, Int'l Application No. PCT/US07/01427 (Atty. Dkt. #639-F-PCT), Filed January 18, 2007, Dated September 26, 2007.	
	9	Beta Glucan Health Center webpage, November 10, 2000, "PLEURAN—Beta-1,3/1-6-Glucan," http://www.glucan.com/therapy/therapy.com .	
	10	BOHN, J.A., and BeMiller, J.N., 1995, "(1→3)-β-Glucans as biological response modifiers: a review of structure-functional activity relationships," Carbohydrate Polymers, 28:3-14.	
	11	CHEUNG, N.-K. V., et al., June 1985, "Monoclonal Antibodies to a Glycolipid Antigen on Human Neuroblastoma Cells," Canc. Res., 45:2642-2649.	
	12	HELLSTROM, I. et al., September 1986, "Antitumor effects of L6, and IgG2a antibody that reacts with most human carcinomas," Proc. Natl. Acad. Sci. USA, 83:7059-7063.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	CHEUNG, Nai-Kong V.
Art Unit	1623
Examiner Name	Eric Olson
Attorney Docket Number	639-B-PCT-US

Sheet 3 of 3

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	13	KIM, Y.-S., et al., October 20, 2000, "Gram-negative Bacteria-binding Protein, a Pattern Recognition Receptor for Lipopolysaccharide and β -1,3-Glucan That Mediates the Signaling for the Induction of Innate Immune Genes in <i>Drosophila melanogaster</i> Cells," <i>J. Biol. Chem.</i> , 275(42):32721-32727.	
	14	KOTERA, Y., et al., June 1, 1994, "Humoral Immunity against a Tandem Repeat Epitope of Human Mucin MUC-1 in Sera from Breast, Pancreatic, and Colon Cancer Patients," <i>Cancer Res.</i> , 54:2856-2860.	
	15	MATZINGER, P., 1994, "Tolerance, Danger, and the Extended Family," <i>Annu. Rev. Immunol.</i> , 12:991-1045.	
	16	MENDELSON, J., December 1997, "Epidermal Growth Factor Receptor Inhibition by a Monoclonal Antibody as Anticancer Therapy," <i>Clin. Cancer Res.</i> , 3:2703-2707.	
	17	RAI, K.R. and GUPTA, N., June 2000, "Monoclonal Antibodies in Chronic Lymphocytic Leukemia," <i>Rev. Clin. Exp. Hematol.</i> , 4:2:134-144.	
	18	SLOVIN, S.F. et al., May 1999, "Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man," <i>Proc. Natl. Acad. Sci. USA</i> , 96:5710-5715.	
	19	ZIMMERMAN, J.W., et al., August 21, 1998, "A Novel Carbohydrate-Glycosphingolipid Interaction between a β -(1-3)-Glucan Immunomodulator, PGG-glucan, and Lactosylceramide of Human Leukocytes," <i>J. Biol. Chem.</i> , 273(34):22014-22020.	
	20	U.S. Office Action for Nai-Kong V. CHEUNG, U.S. Serial No. 11/218,044, Filed August 31, 2005, Dated March 10, 2006 (Atty. Dkt. #639-BZ-PCT-US).	
	21	U.S. Office Action for Nai-Kong V. CHEUNG, U.S. Serial No. 11/218,044, Filed August 31, 2005, Dated November 22, 2006 (Atty. Dkt. #639-BZ-PCT-US).	
	22	U.S. Office Action for Nai-Kong V. CHEUNG, U.S. Serial No. 11/218,044, Filed August 31, 2005, Dated August 7, 2007 (Atty Dkt. #639-BZ-PCT-US).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.